Biogen (BIIB) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Biogen Inc. (BIIB) insider buying and selling: 1 purchase, 5 sales
52 Form 4 Table I transactions filed with the SEC by Biogen Inc. insiders between 2025-09-02 and 2026-10-05 (15-month history): 1 open-market purchase and 5 sales, plus 46 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $532k by Singhal Priya on 2026-02-09.
Biogen insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Biogen insiders filed 1 purchase worth $585 and 4 sales worth $905k on the open market. The net balance is on the sell side: $905k more sold than bought.
The biggest buyer was Murphy Nicole (Head of Pharm Ops and Tech): $585 in 1 purchase, the only buyer. The biggest seller was Singhal Priya (Head of Development): $666k in 2 sales, out of 2 different sellers.
The largest trade of the period was a sale of $532k on Feb 9, 2026, by Singhal Priya (Head of Development), under a 10b5-1 plan. Form 4 on sec.gov (0000875045-26-000023).
All 4 sales carry the 10b5-1 plan flag on the Form 4: scheduled months ahead.
The last three months show 0 purchases and 2 sales, against 0 and 0 in the three before. The latest purchase is from Feb 12, 2026; the latest sale from Aug 4, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Biogen has more sales than 14 of the other 58, ranks 50 of 59 by net dollars sold, and 19 of the 59 have at least one purchase, Biogen included.
The 20 most important trades
The only open-market purchase first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 52 BIIB trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-02-12 | 2026-02-17 | Murphy Nicole | Head of Pharm Ops and Tech | $585 | P — Open-market purchase | SEC |
| 2026-02-09 | 2026-02-10 | Singhal Priya | Head of Development | $532k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-02-02 | 2026-02-03 | Singhal Priya | Head of Development | $134k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-08-03 | 2026-08-05 | Minor Lloyd | Director | $121k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-08-04 | 2026-08-05 | Minor Lloyd | Director | $119k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2025-09-02 | 2025-09-02 | Singhal Priya | Head of Development | $69k | S — Open-market sale (scheduled 10b5-1) | SEC |
| 2026-02-06 | 2026-02-10 | Viehbacher Christopher | President and CEO | $2.2M | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-06 | 2026-02-10 | Alexander Susan H | EVP Chief Legal Officer | $705k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-06 | 2026-02-10 | Murphy Nicole | Head of Pharm Ops and Tech | $672k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2025-12-01 | 2025-12-03 | Viehbacher Christopher | President and CEO | $605k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-06 | 2026-02-10 | Gregory Ginger | EVP, Human Resources | $521k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-06 | 2026-02-10 | Singhal Priya | Head of Development | $497k | F — Tax withholding (shares surrendered for taxes) (scheduled 10b5-1) | SEC |
| 2026-02-06 | 2026-02-10 | Izzar Rachid | Head of Global Product Strat. | $410k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-06 | 2026-02-10 | Keeney Adam | Head of Corporate Development | $318k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-06 | 2026-02-10 | Kramer Robin | Chief Financial Officer | $310k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-06 | 2026-02-10 | Grogan Jane | Head of Research | $199k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2025-08-29 | 2025-09-02 | Singhal Priya | Head of Development | $107k | F — Tax withholding (shares surrendered for taxes) (scheduled 10b5-1) | SEC |
| 2026-01-30 | 2026-02-03 | Singhal Priya | Head of Development | $105k | F — Tax withholding (shares surrendered for taxes) (scheduled 10b5-1) | SEC |
| 2026-05-01 | 2026-05-05 | Keeney Adam | Head of Corporate Development | $85k | F — Tax withholding (shares surrendered for taxes) | SEC |
| 2026-02-06 | 2026-02-10 | Godbout Sean | Chief Accounting Officer | $72k | F — Tax withholding (shares surrendered for taxes) | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Sep 2, 2025 and Oct 5, 2026, Biogen Inc. open-market activity adds up to 1 purchase worth $585 and 5 sales worth $974k. The net balance is $974k on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Biogen Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| M | Option exercise | 19 | $0 |
| F | Tax withholding (shares surrendered for taxes) | 18 | $6.9M |
| A | Grant or award | 9 | $0 |
| S | Open-market sale | 5 | $974k |
| P | Open-market purchase | 1 | $585 |
| Total | Everything filed in the period | 52 | $7.9M |
28 of the 52 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 19 distinct people or entities have filed Biogen Inc. transactions: 1 bought on the open market and 2 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Singhal Priya | Head of Development | 9 | — | $735k (3) | 2026-02-10 |
| Minor Lloyd | Director | 3 | — | $240k (2) | 2026-08-05 |
| Murphy Nicole | Head of Pharm Ops and Tech | 3 | $585 (1) | — | 2026-02-17 |
| Godbout Sean | Chief Accounting Officer | 8 | — | — | 2026-10-05 |
| Grogan Jane | Head of Research | 4 | — | — | 2026-02-10 |
| Keeney Adam | Head of Corporate Development | 4 | — | — | 2026-05-05 |
| Viehbacher Christopher | President and CEO | 4 | — | — | 2026-02-10 |
| Alexander Susan H | EVP Chief Legal Officer | 2 | — | — | 2026-02-10 |
Shown here are the 8 who moved the most money, out of 19. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Feb 2026: 1 purchase and 2 sales, worth $666k. 12 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 1 | $69k |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 0 | $0 |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 1 | $585 | 2 | $666k |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 0 | $0 |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 2 | $240k |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Biogen Inc. (BIIB) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
5 of the 5 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Biogen's single open-market purchase (code P) is the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Oct 5, 2026, and a Form 4 arrives up to two business days after the trade.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.